Pub. Date : 2009 May
PMID : 19552748
10 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 2 | AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 3 | AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 4 | AIMS: The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 5 | CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 6 | CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 7 | CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 8 | CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 9 | CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |
| 10 | CONCLUSION: This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine. | fexofenadine | ATP binding cassette subfamily B member 1 | Homo sapiens |